Division/Committee: [BIOT] Division of Biochemical Technology

It is a very exciting and dynamic time in the field of continuous bioprocessing. Over the past decade, incredible breakthroughs and advancements have made continuous biomanufacturing not just a possibility, but a reality. We are witnessing fully integrated continuous bioprocesses enter commercial readiness and implementation while at the same time pushing the boundaries of productivity. However, most conversations to date have focused on the conversion of “traditional” batch unit operations into continuous versions of the same operation for proteins. This session will focus on disruptive innovations in process technology that are enabled by continuous processing,beyond the current state of the art. How can we further intensify biologics production? Is the future still CHO? What types of separations can be performed with ICB that aren’t feasible in batch mode? How can we make biologics manufacturing more sustainable? We invite submissions that push the boundaries of innovation such as chromatography-free routes to continuous bioprocessing, the developments of novel continuous unit operations required to for further process intensification, and the scientific approaches to address sustainability challenges. Application of strategies for manufacturing emerging modalities employing the concepts of continuous flow and integrated unit operation control strategies are also of interest -- including exosomes/extracellular vesicles, viruses, viral vectors, virus like particles, cells, plasmids and nucleic acids.

Irina Ramos

AstraZeneca PLC

Appearances